Tiva pharmaceutical industries today
TEVA pharmaceutical industries
- 52 weeks
- 11.83 dollars
▼
22.80 dollars
- The target price
- 22.00 dollars
Teva Pharmaceuticals Industries Ltd New York: Tiva It is the largest general drug maker in the world, with more than 500 general and biological treatments in its vast wallet. The medical sector giant also has a group of drugs that lead their growth.
Specialized drugs take specific conditions, including respiratory diseases, oncology, and central nervous system disorders (CNS). Her share took 17 % in the days after the fourth quarter of the 2024 profits. TEVA guidance was launched in 2025 from the estimates of the consensus analyst. With shares trading with only 6.8X profits, valuable investors may look at this as the opportunity to buy a decline.
Transformative year 2024
TEVA Pharmaceuticals, such as many large and democratic drug makers such as Johnson and Johnson New York: JNJand Allergan plc NYSE: AGNand Cvs Health Co. Nyse: cvsAnd Walgrens Boots Alliance Inc. Nasdak: WBAThey participated in the settlements for their participation in the opiate epidemic. The black cloud was dispersed from the Teva surrounding the settlements of opioid materials after 2023, when the company agreed to pay the ongoing payments and provide its public version of Narcan as part of the agreement. This represents 2024 as the year of normalization and return to growth.
Richard Francis, CEO of Teva, commented, “2024, a transformative year for Teva, which led to a second consecutive year of growth, driven by our public products and main innovative products. With a focus on the strict implementation of our axis to the growth strategy throughout the year, we continued to achieve features Important in both its four pillars, including exceeding the expectations of our main innovative products, developing our general business in all sectors, and speeding up early -innovative pipeline, including the results of the positive stage of Duvakitug (Anti -TL1A). The way for the central experiences of Crohn’s disease and ulcerative colitis, as well as, is likely to be, other immune and lobby indicators, in cooperation with our partner, Sanofi.
The conclusion of the year 2024 with a strong end for a solid year
The results of the teva Q4 2024 were relatively strong. The company published the arrow profit of 71 cents, which achieved unanimity estimates.
Revenue decreased by 5.1 % on an annual basis (YO) to $ 4.23 billion, and unanimously won $ 4.23 billion.
For the full year 2024, revenue increased by 6 % year on an annual basis to $ 16.5 billion. Her drugs have grown 15 % in the United States, 6 % in Europe, and 15 % year on an annual basis in international markets. The global sales of its brand medicines were strong.
Osdo exceeded $ 1.6 billion of revenues, exceeding the company’s expectations for 2024.
Ajwa revenue increased by 17 % on an annual basis to $ 507 million. Ozidi’s revenues exceeded $ 100 million, achieving $ 117 million in 2024.
The guidance was on the cautious side
TEVA issued its initial directives for the year 2025 for the full year of EPS from $ 2.35 to $ 2.65 for consensus estimates of $ 2.78. The entire year’s revenues are expected to range between 16.8 billion dollars and 17.4 billion dollars, compared to unanimity estimates of $ 17.09 billion. This is what sparked the sales process.
The first GLP-1 year in the market in 2025
In January 2025, TEVA entered a licensing and supply agreement to treat the proposed GLP-1 in the United States and Europe. The company with the first market is with the launch of a general version of Sandostatin Lar Depot and Liraglutide injection 1.8mg. It is an accredited year of Vicoza.
Liraglutide is a GLP-1 alarm, and it is the active ingredient in Victoza. Victoza is the older GLP-1 Novo Nordisk A/S. NYSE: NVOSemaglutide maker, the active ingredient in Ozmpic and Wegovy. Victoza was an early GLP-1 used specifically for type 2 diabetes, as patients lost on average 6.2 pounds. The way to develop the most modern GLP-1 OzemPIC and then Wegovy weight loss.
TEVA arrow is the collapse of a similar triangle
The similar triangle consists of resistance to the scattered (fallen) upper direction line, converging with the support of the trend lower (height) at the top point. The outbreak occurs when the arrow rises above the resistance of the upper direction line. The collapse occurs when the arrow collapses below the lower direction line support. The collapse or collapse becomes prominent as the arrow approaches the Apex point while the canal narrows.
TEVA formed a similar triangle with the upper significant trend line, which consists at a height of $ 22.80 and supported the symmetrical trend line in the filling of the gap $ 19.03. TEVA was cut towards the Apex point before it decreased in its profits to $ 19.75 and a lesser FIB at a value of $ 17.26. Fibonacci (FIB) withdrawal support levels are $ 17.26, 16.83 dollars, 16.25 dollars and $ 15.81.
The average price of TEVA shares consensus is 23.56 % higher at $ 22.00, and the highest analyst sitting at $ 30.00 sitting. It has six categories to buy analysts and 2 categories. The arrow has a short interest of 1.39 %.
The upscale investors can think about using FIB withdrawals to buy DIP. If the shares are set, the writing of the covered calls at the upper FIB levels implement the wheel strategy for income.
Before you think about Teva Pharmaceutical Industries, you will want to hear it.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts whispered to their customers to buy now before he wiped the broader market … Teva Pharmaceutical Industries was not in the list.
While Teva Pharmaceutical Industries is currently the rating of “moderate purchase” among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
With the spread of data and electric cars, the electrical network will get more tension. Download this report to find out how energy shares can play a role in your wallet with the continued growth of global energy demand.
